{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121103","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.188089+00:00","generated_at":"2026-05-30T05:23:54.008259+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada","bullets":["Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.","CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.","Approximately 40 patients have had cell collections across all regions as of mid-October.","CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.","R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121103","json":"https://secwatch.observer/filing/0000950170-24-121103.json","markdown":"https://secwatch.observer/filing/0000950170-24-121103.md","text":"https://secwatch.observer/filing/0000950170-24-121103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/0000950170-24-121103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024121103/crsp-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:23:54.008259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}